| abstract |
Disclosed herein are compositions and unit dosage forms for the treatment of hepatitis C virus (HCV) infection, including GS-7977 and at least one pharmaceutically acceptable sibling, as well as methods of making such compositions and unit dosage forms. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, comprising administering to the subject an effective amount of GS-7977 and an effective amount of ribavirin for a period of time. In one embodiment, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular embodiment, the method is sufficient to display an undetected amount of HCV RNA in a subject for at least 12 weeks after termination. |